Propionic Acidemia Market Regional Analysis:
North American Market Insights
North America industry is likely to dominate majority revenue share of 35% by 2035, This growth can be attributed to improved healthcare infrastructure, FDA approvals, increased prevalence of propionic acidemia, collaboration and acquisitions with key players and others expected to dominate this region during the forecast period. For example, an orphan drug designation for AAV9hPCCA for the treatment of propionic acidemia was granted by the FDA to the National Center for Advancing Translational Sciences in May 2022.
APAC Market Insights
The propionic acidemia market in the Asia Pacific region is set to grow significantly during the time period between 2026-2035. Newborn screening programs are essential for early diagnosis of propionic acidemia, as early intervention can significantly enhance patient outcomes. The adoption of newborn screening programs is increasing in the Asia Pacific region, which is anticipated to lead toa rise in diagnosed cases of propionic acidemia and consequently the propionic acidemia market.
